Drugs

Warning Letters 2016

These letters are supplied by the CDER Freedom of Electronic Information Office. This page only covers Office of Prescription Drug Promotion (formerly Division of Drug Marketing, Advertising and Communications) and CDER Headquarters Warning Letters.

For District Office Warning Letters see the Main FDA FOI Warning Letters Page.  Some of the letters have been redacted or edited to remove confidential information. Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to: 

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857

Instructions for how to submit an FOI request can be found on the FDA FOI Page.

Office of Prescription Drug Promotion

Company/Individual

Product/Issue

Issue Date

Shionogi Inc.

NDA 022129 ULESFIA (benzyl alcohol) lotion, for topical use

  

3/29/2016

Hospira, Inc., a Pfizer Company

NDA 021038 Precedex (dexmedetomidine hydrochloride) Injection

1/14/2016

 

Office of Compliance/Immediate Office 

Company/Individual

Product/Issue

Issue Date

 

 

 

 

Office of Manufacturing Quality

Company/Individual

Product/Issue

Issue Date

Guangzhou Haishi Biological Technology Co., Ltd.
(WARNING LETTER)

 

CGMP/Finished Pharmaceuticals/Adulterated

6/22/2016

Chongqing Lummy Pharmaceutical Co. Ltd.
(WARNING LETTER
)

CGMP/APIs/Adulterated

6/21/2016

Shanghai Desano Chemical Pharmaceutical Co., Ltd.
(WARNING LETTER)

CGMP/Active Pharmaceutical Ingredients (APIs)/Adulterated

6/16/2016

S.R. Burzynski Manufacturing Facility
(WARNING LETTER)

CGMP/Finished Pharmaceuticals/Adulterated

6/13/2016

Austin Biotechnology Inc.
(WARNING LETTER)

CGMP/Finished Pharmaceuticals/Adulterated

6/2/2016

KO DA Pharmaceutical Co.
(WARNING LETTER)

CGMP/Finished Pharmaceuticals/Adulterated

5/27/2016

Corden Pharma Latina S.p.A.
(WARNING LETTER)

CGMP/Active Pharmaceutical Ingredients (APIs) and finished pharmaceuticals/Adulterated

5/20/2016

Megafine Pharma Limited
(WARNING LETTER)

 

CGMP/Active Pharmaceutical Ingredients (APIs)

5/19/2016

BBT Biotech Gmbh
(WARNING LETTER)

 

CGMP/Active Pharmaceutical Ingredients (APIs)

5/16/2016

Tai Heng Industry Co., Ltd.
(WARNING LETTER)

CGMP/Active Pharmaceutical Ingredients (APIs)

5/12/2016

Polydrug Laboratories Pvt. Ltd.
(WARNING LETTER)

 

CGMP/Active Pharmaceutical Ingredients (APIs)

4/14/2016

Sri Krishna Pharmaceuticals Ltd. - Unit II
(WARNING LETTER)

 

CGMP/Finished Pharmaceuticals/Adulterated

4/1/2016

Emcure Pharmaceuticals Ltd.
(WARNING LETTER)

CGMP/Finished Pharmaceuticals

3/9/2016

Ipca Laboratories Ltd.
(WARNING LETTER)

 

CGMP/Active Pharmaceutical Ingredients (APIs)/Finished Pharmaceuticals/Adulterated

1/29/2016

 

Office of Scientific Investigations

Company/Individual

Product/Issue

Issue Date

Jose Giron, M.D.
(WARNING LETTER)

Clinical Investigator

5/19/2016

Semler Research Center Private Limited
(UNTITLED LETTER)

 

Bioequivalence

4/20/2016

Neuralight HD, LLC
(WARNING LETTER)

Sponsor

4/14/2016

Oeyama-Moto Cancer Research Foundation IRB
(WARNING LETTER)

 

Institutional Review Board

4/7/2016

Oeyama-Moto-Medical Group Foundation, LLC
(WARNING LETTER)

 

Sponsor

3/29/2016

Benedict S. Liao, M.D.
(WARNING LETTER)

 

Clinical Investigator

3/29/2016

Cheta Nand, M.D.  
(WARNING LETTER)

Clinical Investigator

3/10/2016

Pikeville Medical Center Inc. IRB
(WARNING LETTER)

 

Institutional Review Board

3/1/2016

Jamaica Hospital Medical Center IRB
(WARNING LETTER)

Institutional Review Board

2/24/2016

Alexander Neumeister, M.D.
(WARNING LETTER)

Clinical Investigator

2/9/2016

 

Office of Drug Security, Integrity and Recalls

Company/Individual

Product/Issue

Issue Date

Shop Anabolics

Unlawful Sale of Unapproved and Misbranded Drug Products to United States consumers over the Internet

6/2/2016

Steroid Bazaar

Unlawful Sale of Unapproved and Misbranded Drug Products to United States consumers over the Internet

6/2/2016

Pharmaceutical Associates, Inc.

Guaifenesin and Codeine Phosphate 100 mg/10 mg per 5 ml (NDC 0121-1775)

3/23/2016

Moore Medical, LLC

Wallcur LLC’s “Practi-0.9% Sodium Chloride”

1/20/2016

PSS World Medical, Inc.

Wallcur LLC’s “Practi-0.9% Sodium Chloride”

1/20/2016

 

 

Page Last Updated: 07/09/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.